{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:50:04Z","timestamp":1771919404182,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05641-1","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T04:23:21Z","timestamp":1745382201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacotherapy for BPH-related LUTS: associations between medication patterns, persistence, and treatment failure"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-1539","authenticated-orcid":false,"given":"Takeshi","family":"Soda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikari","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Makita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"5641_CR1","doi-asserted-by":"publisher","unstructured":"Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17\u201321. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07497.x","DOI":"10.1111\/j.1464-410X.2008.07497.x"},{"key":"5641_CR2","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/jsm.12525","volume":"11","author":"M Gacci","year":"2014","unstructured":"Gacci M, Ficarra V, Sebastianelli A et al (2014) Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 11:1554\u20131566. https:\/\/doi.org\/10.1111\/jsm.12525","journal-title":"J Sex Med"},{"key":"5641_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11934-020-01009-7","volume":"21","author":"A Sebastianelli","year":"2020","unstructured":"Sebastianelli A, Spatafora P, Morselli S et al (2020) Tadalafil alone or in combination with Tamsulosin for the management for LUTS\/BPH and ED. Curr Urol Rep 21:56. https:\/\/doi.org\/10.1007\/s11934-020-01009-7","journal-title":"Curr Urol Rep"},{"key":"5641_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118\u2013140. https:\/\/doi.org\/10.1016\/j.eururo.2013.03.004","journal-title":"Eur Urol"},{"key":"5641_CR5","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.juro.2009.01.033","volume":"181","author":"MB Nichol","year":"2009","unstructured":"Nichol MB, Knight TK, Wu J et al (2009) Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 181:2214\u20132221. https:\/\/doi.org\/10.1016\/j.juro.2009.01.033","journal-title":"J Urol"},{"key":"5641_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2013.02.026","volume":"64","author":"B Lukacs","year":"2013","unstructured":"Lukacs B, Cornu J-N, Aout M et al (2013) Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: a comprehensive population study. Eur Urol 64:493\u2013501. https:\/\/doi.org\/10.1016\/j.eururo.2013.02.026","journal-title":"Eur Urol"},{"key":"5641_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.eururo.2014.11.006","volume":"68","author":"L Cindolo","year":"2015","unstructured":"Cindolo L, Pirozzi L, Fanizza C et al (2015) Drug adherence and clinical outcomes for patients under Pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68:418\u2013425. https:\/\/doi.org\/10.1016\/j.eururo.2014.11.006","journal-title":"Eur Urol"},{"key":"5641_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1557988315616676","volume":"11","author":"E Shortridge","year":"2017","unstructured":"Shortridge E, Donatucci C, Donga P et al (2017) Adherence and persistence patterns in medication use among men with lower urinary tract symptoms\/benign prostatic hyperplasia. Am J Mens Health 11:164\u2013169. https:\/\/doi.org\/10.1177\/1557988315616676","journal-title":"Am J Mens Health"},{"key":"5641_CR9","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00345-020-03429-z","volume":"39","author":"HT Ayele","year":"2021","unstructured":"Ayele HT, Reynier P, Azoulay L et al (2021) Trends in the Pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study. World J Urol 39:2019\u20132028. https:\/\/doi.org\/10.1007\/s00345-020-03429-z","journal-title":"World J Urol"},{"key":"5641_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/nau.24348","volume":"39","author":"AL Burnett","year":"2020","unstructured":"Burnett AL, Walker DR, Feng Q et al (2020) Undertreatment of overactive bladder among men with lower urinary tract symptoms in the united States: A retrospective observational study. Neurourol Urodyn 39:1378\u20131386. https:\/\/doi.org\/10.1002\/nau.24348","journal-title":"Neurourol Urodyn"},{"key":"5641_CR11","doi-asserted-by":"publisher","first-page":"e14250","DOI":"10.1111\/ijcp.14250","volume":"75","author":"B Mi\u00f1ana","year":"2021","unstructured":"Mi\u00f1ana B, Molero JM, Agra Rol\u00e1n A et al (2021) Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain. Int J Clin Pract 75:e14250. https:\/\/doi.org\/10.1111\/ijcp.14250","journal-title":"Int J Clin Pract"},{"key":"5641_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0094-0143(21)00666-2","volume":"22","author":"MJ Barry","year":"1995","unstructured":"Barry MJ, O\u2019Leary MP (1995) Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin North Am 22:299\u2013307","journal-title":"Urol Clin North Am"},{"key":"5641_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","volume":"68","author":"Y Homma","year":"2006","unstructured":"Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 68:318\u2013323. https:\/\/doi.org\/10.1016\/j.urology.2006.02.042","journal-title":"Urology"},{"key":"5641_CR14","unstructured":"Cornu JN, Gacci M, Hashim H et al (2023) EAU guidelines on Non-Neurogenic male lower urinary tract symptoms (LUTS), incl. In: EAU Guidelines. Benign Prostatic Obstruction (BPO)"},{"key":"5641_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P et al (2024) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol 211:11\u201319. https:\/\/doi.org\/10.1097\/JU.0000000000003698","journal-title":"J Urol"},{"key":"5641_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2006.06.012","volume":"51","author":"A Hutchison","year":"2007","unstructured":"Hutchison A, Farmer R, Verhamme K et al (2007) The efficacy of drugs for the treatment of Luts\/BPH, A study in 6 European countries. Eur Urol 51:207\u2013216. https:\/\/doi.org\/10.1016\/j.eururo.2006.06.012","journal-title":"Eur Urol"},{"key":"5641_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.urology.2023.06.029","volume":"180","author":"S Neu","year":"2023","unstructured":"Neu S, Matta R, Locke J et al (2023) Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications in Canada: A retrospective population-based study. Urology 180:219\u2013226. https:\/\/doi.org\/10.1016\/j.urology.2023.06.029","journal-title":"Urology"},{"key":"5641_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12894-021-00881-w","volume":"21","author":"M Ali","year":"2021","unstructured":"Ali M, Landeira M, Covernton PJO et al (2021) The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study. BMC Urol 21:119. https:\/\/doi.org\/10.1186\/s12894-021-00881-w","journal-title":"BMC Urol"},{"key":"5641_CR19","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of Doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387\u20132398. https:\/\/doi.org\/10.1056\/NEJMoa030656","journal-title":"N Engl J Med"},{"key":"5641_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and Tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the combat study. Eur Urol 57:123\u2013131. https:\/\/doi.org\/10.1016\/j.eururo.2009.09.035","journal-title":"Eur Urol"},{"key":"5641_CR21","doi-asserted-by":"publisher","unstructured":"Zabkowski T, Saracyn M (2018) Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia. J Physiol Pharmacol 69. https:\/\/doi.org\/10.26402\/jpp.2018.4.14","DOI":"10.26402\/jpp.2018.4.14"},{"key":"5641_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/bco2.74","volume":"2","author":"S Malde","year":"2021","unstructured":"Malde S, Lam W, Adwin Z, Hashim H (2021) Pharmacological and interventional treatment of benign prostatic obstruction: an evidence-based comparative review. BJUI Compass 2:238\u2013259. https:\/\/doi.org\/10.1002\/bco2.74","journal-title":"BJUI Compass"},{"key":"5641_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/nau.23276","volume":"37","author":"JT Anger","year":"2018","unstructured":"Anger JT, Goldman HB, Luo X et al (2018) Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the united States. Neurourol Urodyn 37:213\u2013222. https:\/\/doi.org\/10.1002\/nau.23276","journal-title":"Neurourol Urodyn"},{"key":"5641_CR24","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/nau.24527","volume":"39","author":"T Soda","year":"2020","unstructured":"Soda T, Tashiro Y, Koike S et al (2020) Overactive bladder medication: persistence, drug switching, and reinitiation. Neurourol Urodyn 39:2527\u20132534. https:\/\/doi.org\/10.1002\/nau.24527","journal-title":"Neurourol Urodyn"},{"key":"5641_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.juro.2017.05.031","volume":"198","author":"Y Matsukawa","year":"2017","unstructured":"Matsukawa Y, Takai S, Funahashi Y et al (2017) Effects of withdrawing \u03b11-blocker from combination therapy with \u03b11-blocker and 5\u03b1-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A prospective and comparative trial using urodynamics. J Urol 198:905\u2013912. https:\/\/doi.org\/10.1016\/j.juro.2017.05.031","journal-title":"J Urol"},{"key":"5641_CR26","doi-asserted-by":"publisher","first-page":"e030405","DOI":"10.1136\/bmjopen-2019-030405","volume":"9","author":"H van der Worp","year":"2019","unstructured":"van der Worp H, Jellema P, Hordijk I et al (2019) Discontinuation of alpha-blocker therapy in men with lower urinary tract symptoms: a systematic review and meta-analysis. BMJ Open 9:e030405. https:\/\/doi.org\/10.1136\/bmjopen-2019-030405","journal-title":"BMJ Open"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05641-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05641-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05641-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:54:05Z","timestamp":1767966845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05641-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5641"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05641-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the Medical Research Institute Kitano Hospital, approval number [P220901400].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was waived by the Institutional Review Board of the Medical Research Institute Kitano Hospital in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}